Propanc Biopharma Raises Up to $100M for Crypto Treasury Boost

As the integration of blockchain and biotechnology progresses, more companies are exploring innovative ways to leverage cryptocurrency assets for strategic growth. Recently, Propanc Biopharma, an Australia-based biotech firm focusing on cancer therapies, announced a groundbreaking move to establish a crypto treasury with the backing of a crypto-focused family office. This development marks a significant step toward merging healthcare innovation with the evolving world of digital assets, highlighting a trend where biotech firms are increasingly embracing crypto strategies to fund research and development.

Australia-based Propanc Biopharma has announced a substantial funding agreement with Hexstone Capital, a family office that specializes in digital assets. The private placement involves $100 million, structured through convertible preferred stock, with an initial investment of $1 million and potential follow-on funding of up to $99 million over the next year. The move is aimed at creating a dedicated digital asset treasury to support the company’s development of innovative cancer treatments.

The company highlighted that the proceeds from this funding will help accelerate the clinical development of its lead product, PRP, which focuses on proenzyme-based oncology therapies. PRP aims to enter first-in-human trials in the latter half of 2026, marking a key milestone for Propanc. CEO James Nathanielsz emphasized that the crypto treasury would play a transformative role by strengthening the firm’s financial position and facilitating advancements in its biotech pipeline.

“We can target not only patients suffering from metastatic cancer from solid tumors, but several chronic diseases based upon the mechanism of action of proenzyme therapy,” Nathanielsz stated.

While Propanc did not specify which digital assets it plans to acquire, Hexstone’s investment portfolio includes holdings in prominent cryptocurrencies like Bitcoin (BTC), Ether (ETH), Solana (SOL), and Injective (INJ). This strategic move reflects an increasing trend among biotech companies adopting crypto strategies to appeal to investors and fund cutting-edge research.

Biotech companies adopting a crypto strategy

Propanc joins a growing list of biotech firms, including Sonnet BioTherapeutics and Sharps Technology, that are turning to crypto and blockchain-based assets to rekindle investor interest amid volatile markets. However, such initiatives have not always been well received by the market. Following Propanc’s announcement, its shares declined by 10.5% on the Nasdaq, illustrating the cautious sentiment surrounding crypto-driven strategies in the biomedical sector.

Crypto treasury strategies face recent hurdles

The enthusiasm for corporate crypto treasuries has waned recently as many organizations face losses and market downturns. Bitcoin treasury holding companies, once seen as strategic assets, have experienced significant declines, with some firms offloading portions of their holdings to cover debts or preserve liquidity. Major players like Strategy, the largest corporate Bitcoin holder, have seen their market cap decrease by over 43% since July, illustrating the volatile environment that still challenges crypto adoption within corporate finance.

Additionally, stocks like Metaplanet, which performed well earlier this year, have plunged approximately 55% since June, further underscoring market turbulence. Despite these setbacks, the integration of blockchain and digital assets into corporate strategies continues to gain traction among various sectors looking to diversify funding sources and capitalize on the growing crypto ecosystem.